Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.

GlobeNewsWire • Sep 1, 2026

Pulmonx to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:

GlobeNewsWire • Aug 27, 2026

Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?

After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Zacks Investment Research • Aug 26, 2026

Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year

Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.

MarketBeat • Aug 15, 2026

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?

Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Aug 14, 2026

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?

Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Aug 3, 2026

Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript

Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 30, 2026

Pulmonx Q2 Earnings Call Highlights

Pulmonx NASDAQ: LUNG reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China.

MarketBeat • Jul 29, 2026

Pulmonx Reports Second Quarter 2026 Financial Results

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026.

GlobeNewsWire • Jul 29, 2026

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.38 per share a year ago.

Zacks Investment Research • Jul 29, 2026